CLARIFY: ADH1 and ADH2 Disease Monitoring Study (DMS)

Condition:   Autosomal Dominant Hypocalcemia Intervention:   Sponsor:   Calcilytix Therapeutics, Inc., a BridgeBio company Recruiting

Source: ClinicalTrials.gov - February 7, 2022 Category: Research Source Type: clinical trials